GlassScriptPhysician profile
Alejandro Garcia
NPI 1114000569
$4,806.08
in general payments reported to CMS, 2019-2025
24 companies · $499 in 2025
The $499 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $594 · 2021: $737 · 2022: $767 · 2023: $897 · 2024: $887 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,282.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $866.71 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $663.29 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $505.34 | 2020-2025 | Farxiga, Andexxa |
| Boston Scientific Corporation | $461.49 | 2019-2025 | Watchman Access System, Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $415.60 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $343.27 | 2019-2024 | Xarelto |
| Medtronic, INC. | $332.13 | 2021-2023 | Micra, Linq II |
| Merck Sharp & Dohme LLC | $257.30 | 2021-2025 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $224.24 | 2024 | Arcalyst |
| Abbott Laboratories | $147.05 | 2019-2024 | Aveir |
| Esperion Therapeutics, INC. | $130.30 | 2020-2025 | Nexletol |
| Kiniksa Pharmaceuticals, LTD. | $96.15 | 2022-2023 | Arcalyst |
| Pfizer INC. | $85.48 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $50.34 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.25 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $37.90 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $36.87 | 2019 | |
| Insulet Corporation | $23.78 | 2023 | Omnipod |
| Lexicon Pharmaceuticals, INC. | $18.92 | 2024 | |
| Halozyme INC | $16.99 | 2023 | |
| Abiomed | $16.34 | 2020 | |
| Alnylam Pharmaceuticals INC. | $14.83 | 2023 | Onpattro |
| Irhythm Technologies, INC. | $13.15 | 2022 | |
| Cardiovascular Systems INC. | $5.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.